Oncology Companion Diagnostic Market
Report ID: SQMIG35A3393
Report ID: SQMIG35A3393
[email protected]
USA +1 351-333-4748
Report ID:
SQMIG35A3393 |
Region:
Global |
Published Date: May, 2026
Pages:
157
|Tables:
179
|Figures:
79
Global Oncology Companion Diagnostic Market size was valued at USD 4.6 Billion in 2024 and is poised to grow from USD 5.02 Billion in 2025 to USD 10.07 Billion by 2033, growing at a CAGR of 9.1% during the forecast period (2026-2033).
The primary driver of the oncology companion diagnostic market is the rapid shift toward precision oncology, where molecular tests determine therapeutic eligibility and predict response. Companion diagnostics are tests that are developed in conjunction with a targeted treatment to help determine which patients will respond the best to that treatment. IT improve clinical outcomes and lower the cost of treatment while also minimizing exposure to unnecessary toxicities. The market began with early examples of testing for HER2 along with the drug trastuzumab to identify patients who were most likely to benefit from the drug. As more regulatory agencies have developed regulations around or encouraged the use of companion diagnostics, investment and use have increased and thus accelerated the development of diagnostics.
A key trend driving the global oncology companion diagnostic sector is technological advancement in high-throughput sequencing and biomarker multiplexing, because lower sequencing costs and bioinformatics enable broader panels that identify actionable alterations across tumor types. Through the utilization of NGS panels, oncologists can effectively identify the use of therapies already approved for patients with rare fusions or resistance mutations. One example was the identification of patients through liquid biopsy with the EGFR T790M mutation that led them to receive osimertinib without repeating a tissue biopsy. Improvements in the standardization of PD-L1 assays as they relate to patient eligibility for immunotherapy have allowed payers/insurers to approve tests and developers to pursue companion diagnostics. There has been an increase in collaboration between diagnostic companies and pharmaceutical companies and many commercial opportunities associated with reimbursement, international expansion of adaptive trial design, and commercialization of products.
How is AI Transforming the Oncology Companion Diagnostic Market?
Oncology companion diagnostics are being transformed by AI's ability to turn complicated datasets into a more manageable, functional format while improving the interconnectivity of diagnostic products to their relevant targeted therapeutics. Key components of this transformation include AI powered image analysis for enhancing pathological diagnosis, machine learning for interpretation of genomic and RNA signals, and other tools that will improve both assay development and trial readiness for pharmaceutical products. Currently in the market are both established molecular tests and new AI-enabled approaches with increasing levels of collaboration between diagnostic manufacturers and sponsors. This shift is increasing the pace at which biomarkers move from discovery to clinical decision support and is making companion diagnostics more adaptive to tumor biology and clinical needs.
In May 2026, Roche announced a definitive agreement to acquire PathAI which accelerates integration of AI driven digital pathology into companion diagnostic pipelines. This supports market efficiency by pairing AI model development with diagnostic scale and by shortening the time needed to validate image based biomarkers for therapy selection.
Market snapshot - (2026-2033)
Global Market Size
USD 4.6 Billion
Largest Segment
OTT Devices
Fastest Growth
OTT Services
Growth Rate
9.1% CAGR
To get more insights on this market click here to Request a Free Sample Report
Global oncology companion diagnostic market is segmented by component, deployment type, revenue model, application, device type, end user and region. Based on component, the market is segmented into OTT devices and OTTservices. Based on deployment type, the market is segmented into cloud-based OTT services, on-premises OTT platforms and hybrid OTT platforms. Based on revenue model, the market is segmented into subscription-based, advertising-based, transaction-based and hybrid revenue models. Based on application, the market is segmented into entertainment & media, education & e-learning, gaming, communication & collaboration, fitness & wellness and others. Based on device type, the market is segmented into smartphones & tablets, smart tvs, laptops & pcs, streaming devices, gaming consoles and others. Based on end user, the market is segmented into residential consumers, commercial users, educational institutions, enterprises and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Cloud based OTT services segment dominates because centralized, scalable platforms enable real time aggregation and analytics of companion diagnostic results, linking laboratory outputs with clinical decision support. The ability to communicate with EHRs and telemedicine systems helps make the use of biomarker-driven therapies easier, leading to an increased rate of use at diagnostic labs and oncology businesses. These assays can be quickly deployed in different environments while maintaining up-to-date software through and ongoing process of system enhancements. Consequently, these trends demonstrate ongoing leadership in improving the speed of time from testing to treatment through continual development of AI algorithms.
However, hybrid OTT platforms are the fastest growing area due to their ability to combine local data control with cloud scalability, appealing to labs requiring data privacy while benefiting from centralized analytics. Rising demand for flexible deployment, regulatory alignment for sensitive genomic data, and vendor investment in edge and cloud orchestration are accelerating uptake and creating new integration opportunities.
Subscription based segment dominates because predictable revenue streams enable diagnostics companies to invest in long term assay development, post market support, and integrated clinical decision tools tailored for oncology. With continuous updates of companion diagnostics being prompted for ongoing access, as well as updated biomarker discovery by vendors, their business interests will be aligned with the desired clinical outcomes. This model also facilitates bundled service offerings that eliminate barriers to hospital/laboratory adoption and build long-term partnerships to promote lifecycle and evidence management.
Conversely, hybrid revenue models are gaining rapid traction as they blend subscriptions, per test fees, and outcome based contracts to meet diverse payer and provider needs. Flexibility attracts oncology centers and diagnostic developers seeking risk sharing and value alignment, stimulating innovative pilot programs and unlocking new reimbursement pathways that expand commercial feasibility for companion diagnostics.
To get detailed segments analysis, Request a Free Sample Report
As per the global oncology companion diagnostic market share, North America dominates the industry due to an integrated ecosystem that combines advanced research institutions, established diagnostic manufacturers, strong clinical trial activity, and favorable regulatory pathways. Collaboration of academic institutions, biotech companies, and diagnostic tests accelerates conversion from biomarkers to validated assays. Clinical acceptance of targeted therapy supported by companion diagnostic uses payer structures and reimbursement mechanisms. Investments from companies for infrastructure related to precision oncology will also assist with laboratory capacity and commercialization of assays. A high level of clinician familiarity with molecular testing, coupled with widespread hospital and laboratory networks, enables rapid implementation across care pathways. This combination of scientific leadership, commercial scale, and supportive health system structures sustains market leadership and broad stakeholder alignment.
Oncology companion diagnostic market in United States benefits from concentrated biopharma activity, extensive clinical research networks, and a well developed regulatory and reimbursement environment that encourages test development and clinical integration. Leading diagnostic companies and reference laboratories drive assay innovation. Physicians possess high familiarity with genomic testing and multidisciplinary oncology teams support guideline adoption. Strong venture and institutional funding supports commercialization pathways and rapid translation of biomarker discoveries into clinical diagnostics.
Oncology companion diagnostic market in Canada combines centralized public health laboratories, growing private diagnostic networks, and focused investment in molecular oncology to support test adoption and clinical validation. Standardized testing pathways are supported by provincial policies, collaboratives among hospitals and research institutes, as well as laboratory accreditation and engagement of payors. In addition, there is a global diagnostics industry through local companies and working with international diagnostic companies to enable the transfer of technology. This has resulted in improved service of diagnostics across all delivery systems.
Based on global oncology companion diagnostic regional forecast, Europe is expanding rapidly due to coordinated regulatory frameworks, strong academic clinical partnerships, and increasing harmonization of testing standards across member states. Through collaborative research consortia and a pan-regional initiative, publicly funded institutions can facilitate both common biomarker validation efforts and cross-border clinical studies. By utilizing centrally coordinated laboratory networks, researchers can access more advanced diagnostic tests. Increased focus on precision medicine in clinical guidelines has also encouraged payers to discuss the use of companion diagnostics for routine clinical purposes in a proactive manner. The large number of innovative diagnostic companies in Europe combined with the high level of translational research capability amongst many of the leading centres across Europe creates a rapidly commercialised and diffused test market placing Europe at the forefront of the developing and adopting companion diagnostics.
Oncology companion diagnostic market in Germany demonstrates leadership through strong translational research institutions and extensive clinical trial infrastructure. Through collaborative networks created by university hospitals working with diagnostic companies, biomarkers can be validated and multicenter studies performed. Supporting biomarker clinical use includes standard laboratory accreditation processes, well defined regulatory interactions with national regulatory bodies, and paying for oncologic care provided according to established guidelines. Local innovation clusters will facilitate commercialisation of new technologies and foster partnerships with international diagnostic corporations.
Oncology companion diagnostic market in United Kingdom is driven by coordinated national genomic programs, integrated laboratory networks, and strong links between academic centers and clinical services. Centralized commissioning and pilot initiatives enable faster adoption of validated assays, and clinician education supports guideline uptake. There has been a genuine willingness by the UK government to support the development of diagnostic innovations and the engagement of actively involved patients with the aim to develop new partnerships and find commercial outlets for the implementation of companion diagnostics across the UK.
Oncology companion diagnostic market in France is emerging through research excellence, regional cancer networks, and growing industry collaboration focused on assay development and clinical validation. Molecular pathology units and testing centers in hospitals increase the level of access to higher-level diagnostic methods and services. Payers will encourage the use of these new diagnostic capabilities, as will various policy initiatives. Businesses are teaming with clinical care centers to promote the transfer of technologies between industries.
As per global oncology companion diagnostic regional outlook, Asia Pacific is strengthening its position in the industry through targeted national strategies, investment in precision medicine infrastructure, and increasing collaboration with global diagnostic developers. Increasing domestic capacity in genomics technologies, the growth of laboratory networks, and improved regulatory engagement will enable local validation and clinical use of companion diagnostics. Funds generated by public and private funding programs in conjunction with clinician training programs are creating opportunities for the integration of molecular diagnostics into oncology care. Through cross-border relationships and licensing agreements, there are more opportunities for technology transfer and commercialization while clinical research undertaken locally will provide evidence for relevant biomarkers. Collectively, these factors contribute to a progressive transition from imported technology to Indigenous innovation and an expanded regional availability of companion diagnostics.
Oncology companion diagnostic market in Japan is supported by strong domestic diagnostic manufacturers, established clinical research institutions, and an evolving regulatory environment that facilitates assay validation and market entry. Hospital based molecular laboratories and specialized oncology centers enable adoption and multicenter studies. The implementation of commercial testing powered by government-sponsored initiatives and working with businesses to develop biomarkers for the marketplace will be supported by a collaborative approach among payers, regulators and developers.
Oncology companion diagnostic market in South Korea benefits from a dynamic biotechnology sector, collaboration between hospitals and diagnostic developers, and proactive regulatory engagement that supports local assay validation. Academic institutions and private lab networks support clinical acceptance and study. Targeted government programs and public-private partnerships enable commercial scale-up and collaboration. Advanced companion diagnostics will become a standard part of oncology practice due to strong manufacturing capacity, export strategies attracting investment, and integration of advanced companion diagnostics into standard oncology practice.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Rising Precision Medicine Adoption
Regulatory Support For Diagnostics
High Development and Validation Costs
Limited Reimbursement and Coverage
Request Free Customization of this report to help us to meet your business objectives.
Competitive dynamics in the global oncology companion diagnostic market outlook center on strategic alliances, regulatory positioning, and technology differentiation as firms pursue co development, label secured CDx and platform integration to win pharma partnerships. Recent activity illustrates M&A driven consolidation such as Roche acquiring Foundation Medicine, co development and commercialization partnerships like Illumina with Boehringer Ingelheim, and custom CDx alliances exemplified by QIAGEN and Sysmex.
Top Player’s Company Profile
Recent Developments
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
As per SkyQuest analysis, the global oncology companion diagnostic industry is propelled by a key driver in the shift toward precision oncology that links molecular testing to targeted therapies and improves outcomes while guiding treatment selection. A second driver is rapid AI adoption that accelerates biomarker discovery and enables interpretable genomic and image analysis. A restraint is the high costs of development validation and regulatory approval that limit new entrants and slow novel assay commercialization. The dominating region is North America supported by strong research reimbursement frameworks and clinical infrastructure. The dominating segment is cloud-based OTT services whose scalable interoperable platforms streamline diagnostic data workflows and clinical decision support.
| Report Metric | Details |
|---|---|
| Market size value in 2024 | USD 4.6 Billion |
| Market size value in 2033 | USD 10.07 Billion |
| Growth Rate | 9.1% |
| Base year | 2024 |
| Forecast period | (2026-2033) |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Oncology Companion Diagnostic Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Oncology Companion Diagnostic Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Oncology Companion Diagnostic Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Oncology Companion Diagnostic Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
REQUEST FREE CUSTOMIZATION
Global Oncology Companion Diagnostic Market size was valued at USD 4.6 Billion in 2024 and is poised to grow from USD 5.02 Billion in 2025 to USD 10.07 Billion by 2033, growing at a CAGR of 9.1% during the forecast period (2026-2033).
Competitive dynamics in the global oncology companion diagnostic market center on strategic alliances, regulatory positioning, and technology differentiation as firms pursue co development, label secured CDx and platform integration to win pharma partnerships. Recent activity illustrates M&A driven consolidation such as Roche acquiring Foundation Medicine, co development and commercialization partnerships like Illumina with Boehringer Ingelheim, and custom CDx alliances exemplified by QIAGEN and Sysmex. 'Netflix', 'Amazon Prime Video', 'Disney+', 'Hulu', 'Apple TV+', 'YouTube', 'Spotify', 'Tencent Video', 'Roku', 'Google', 'Samsung Electronics', 'Sony Group', 'Microsoft', 'Warner Bros. Discovery', 'Paramount Global', 'Comcast', 'ByteDance', 'iQIYI', 'DAZN', 'Zoom Communications'
Advances in precision medicine and increasing focus on targeted therapies promote adoption of companion diagnostics by enabling more accurate patient stratification, informing therapeutic selection, and reducing trial failures. As oncologists prioritize matching treatments to molecular profiles, demand for reliable diagnostic assays grows because they directly influence clinical decision making and perceived treatment value. Industry stakeholders invest in developing robust diagnostic platforms and integrating biomarker knowledge into clinical workflows, which strengthens clinical utility and confidence among payers and clinicians, thereby supporting broader market expansion and sustained uptake.
Precision Medicine Integration: Adoption of companion diagnostics is increasingly aligned with broader precision medicine strategies, driving collaboration between diagnostic developers and therapeutic manufacturers. This trend emphasizes tailored testing pathways that inform targeted treatment selection and monitor therapeutic response, fostering closer integration across clinical workflows and care teams. Market participants prioritize scalable platforms and interoperable data systems to support clinical decision making, while payers and providers show growing interest in aligning diagnostic use with long term patient management objectives and value based care models.
Why does North America Dominate the Global Oncology Companion Diagnostic Market? |@12
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
USA (+1) 351-333-4748
